Literature DB >> 15161694

Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors.

Andreas Widschwendter1, Conny Gattringer, Lennart Ivarsson, Heidi Fiegl, Alois Schneitter, Angela Ramoni, Hannes M Müller, Annemarie Wiedemair, Susanne Jerabek, Elisabeth Müller-Holzner, Georg Goebel, Christian Marth, Martin Widschwendter.   

Abstract

PURPOSE: Cancer of the uterine cervix is an important cause of death in women worldwide. Pap smears as a tool for screening decreased the incidence and mortality of cervical cancer dramatically. This proof of principle study aimed to develop a potential tool for cervical screening using a test that can be applied by patients without visiting a physician and to increase the coverage rate, especially of the high-risk population with low socioeconomic status. EXPERIMENTAL
DESIGN: Human papillomavirus (HPV) DNA testing and methylation analysis of DNA obtained from cervicovaginal specimens of 13, 31, and 11 patients with no dysplasia/low-grade squamous intraepithelial lesion (SIL), high-grade SIL, and invasive cervical cancer, respectively, collected on a tampon, was performed using PCR-based methods to detect invasive cervical cancer and study whether these changes are already present in the precursor lesions.
RESULTS: High-risk HPV DNA was present in 68 and 82% of patients with high-grade SIL and invasive cervical cancer. DNA methylation of the 11 genes tested increased with severity of the cervical lesion. Unsupervised hierarchical cluster analysis using solely information on DNA methylation of the 11 genes was able to predict the presence of invasive cervical cancers: one of the two clusters formed contained 9 of 11 invasive cervical cancers, as well as two high-grade SILs.
CONCLUSIONS: HPV DNA and DNA methylation analyzed in cervicovaginal specimens are able to predict invasive cervical cancers. To detect all high-grade SILs when applying this test, genes that become methylated earlier throughout cervical carcinogenesis have to be defined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161694     DOI: 10.1158/1078-0432.CCR-03-0143

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes.

Authors:  Denise M Schütze; Jan M Kooter; Saskia M Wilting; Chris J L M Meijer; Wim Quint; Peter J F Snijders; Renske D M Steenbergen
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

Review 2.  Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions.

Authors:  Renske D M Steenbergen; Peter J F Snijders; Daniëlle A M Heideman; Chris J L M Meijer
Journal:  Nat Rev Cancer       Date:  2014-06       Impact factor: 60.716

Review 3.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Folate deficiency and aberrant DNA methylation and expression of FHIT gene were associated with cervical pathogenesis.

Authors:  Qiaoling Li; Ling Ding; Nan Jing; Chunliang Liu; Zuokai Yang; Fang Chen; Lifang Hou; Jintao Wang
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

5.  Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.

Authors:  Chiaki Banzai; Koji Nishino; Jinhua Quan; Kosuke Yoshihara; Masayuki Sekine; Tetsuro Yahata; Kenichi Tanaka
Journal:  Int J Clin Oncol       Date:  2013-03-14       Impact factor: 3.402

6.  Methylation analysis of SFRP genes family in cervical adenocarcinoma.

Authors:  Ya-Wen Lin; Ming-Tzeung Chung; Hung-Cheng Lai; Ming De Yan; Yu-Leung Shih; Cheng-Chang Chang; Mu-Hsien Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

Review 7.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

Review 8.  Application of DNA methylation biomarkers for endometrial cancer management.

Authors:  Shi-Wen Jiang; Jinping Li; Karl Podratz; Sean Dowdy
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

9.  Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer.

Authors:  Vera N Senchenko; Natalia P Kisseljova; Tatyana A Ivanova; Alexey A Dmitriev; George S Krasnov; Anna V Kudryavtseva; Grigory V Panasenko; Evgeny B Tsitrin; Michael I Lerman; Fyodor L Kisseljov; Vladimir I Kashuba; Eugene R Zabarovsky
Journal:  Epigenetics       Date:  2013-03-11       Impact factor: 4.528

10.  Discovery and validation of methylation markers for endometrial cancer.

Authors:  Nicolas Wentzensen; Jamie N Bakkum-Gamez; J Keith Killian; Joshua Sampson; Richard Guido; Andrew Glass; Lisa Adams; Patricia Luhn; Louise A Brinton; Brenda Rush; Lori d'Ambrosio; Munira Gunja; Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Jolanta Lissowska; Karl Podratz; Paul Meltzer; Viji Shridhar; Mark E Sherman
Journal:  Int J Cancer       Date:  2014-03-31       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.